Use of the negr1 protein and biologically active fragments thereof in the therapeutic treatment of alk-related diseases
AssigneesFondazione Telethon Ets (70%), Universita' Degli Studi Di Trento (30%)
InventorsGiovanni Piccoli, Francesca Pischedda
Life of this patent
Estimating the term…
Abstract
The invention relates to novel Negr1 protein fragments having ALK-inhibiting or ALK-reducing activity and to the nucleic acids encoding therefor, as well as to the use of the Negr1 protein, its fragments and the nucleic acids encoding therefor in the therapeutic treatment of ALK-related diseases such as cancer and tauopathies.
Claims19
Method of therapeutically treating a disease selected from a tumor disease and a tauopathy in a patient in need thereof with an isolated Negr1 protein or a biologically active fragment thereof of at least 6 amino acids in length capable of reducing ALK protein expression levels, said method comprising
- administering to said patient a therapeutically effective amount of said Negr1 protein or of said biologically active fragment thereof of at least 6 amino acids in length.
-7. (canceled)
An isolated peptide or polypeptide of at least 6 amino acids in length, which is a fragment of a Negr1 protein and is capable of reducing ALK protein expression levels, wherein said fragment is selected from the group consisting of:
- (i) amino acid sequences which comprise SEQ ID NO:
- 1, SEQ ID NO:2, SEQ ID NO:
- 3, SEQ ID NO:4 or SEQ ID NO:5;
- and
- (ii) amino acid sequences which comprise an amino acid sequence at least 90% identical to SEQ ID NO:
- 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:
- 5.
(canceled)
-23. (canceled)
(canceled)
Dependencies are inferred from the claim text.